Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 1, 2009, Pages 20-38

  Altinok, Atilla ^a   Lévi, Francis ^b,c,d   Goldbeter, Albert ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Cancer Chronotherapy; Cell Cycle; Chronotolerance; Circadian Rhythms; Glutathione; Model

Indexed keywords

FLUOROURACIL; GLUTATHIONE; OXALIPLATIN; PROTEIN BMAL1; THIOL; THIOL DERIVATIVE; TRANSCRIPTION FACTOR CLOCK;

ARTICLE; AUTOMATON MODEL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CHRONOEFFICACY; CHRONOPHARMACOLOGY; CHRONOTHERAPY; CHRONOTOLERANCE; CIRCADIAN RHYTHM; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG MECHANISM; HOMEOSTASIS; HUMAN; MITOSIS; MODEL; NONHUMAN; PRIORITY JOURNAL;

ALGORITHMS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL CYCLE; CIRCADIAN RHYTHM; FLUOROURACIL; GLUTATHIONE; HUMANS; MODELS, STATISTICAL; ORGANOPLATINUM COMPOUNDS;

EID: 58149112145     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.10.024     Document Type: Article

References (54)

1. Altinok A., Lévi F., and Goldbeter A. A cell cycle automaton model for probing circadian patterns of anticancer drug delivery. Adv. Drug Deliv. Rev. 59 (2007) 1036-1053
2. Altinok A., Lévi F., and Goldbeter A. Optimizing temporal patterns of anticancer drug delivery by simulations of a cell cycle automaton. In: Bertau M., Mosekilde E., and Westerhoff H.V. (Eds). Biosimulation in Drug Development (2007), Wiley-VCH, Weinheim 275-297
3. Bjarnason G.A., and Jordan R. Circadian variation of cell proliferation and cell cycle protein expression in man: clinical implications. Prog. Cell Cycle Res. 4 (2000) 193-206
4. Bjarnason G.A., Jordan R.C.K., Wood P.A., Li Q., Lincoln D.W., Sothern R.B., Hrushesky W.J.M., and Ben-David Y. Circadian expression of clock genes in human oral mucosa and skin. Am. J. Pathol. 158 (2001) 1793-1801
5. Boughattas N., Lévi F., Fournier C., Lemaigre G., Roulon A., Hecquet B., Mathé G., and Reinberg A. Circadian rhythms in toxicities and tissues uptake of oxaliplatin in mice. Cancer Res. 49 (1989) 3362-3368
6. Bridges A.B., Fisher T.C., Scott N., McLaren M., and Belch J.J.F. Circadian rhythm of white blood cell aggregation and free radical status in healthy volunteers. Free Radic. Res. Commun. 16 (1992) 89-97
7. Brooks R.F., Bennett D.C., and Smith J.A. Mammalian cell cycles need two random transitions. Cell 19 (1980) 493-504
8. Burns E.R., and Beland S.S. Effect of biological time on the determination of the LD50 of 5-fluorouracil in mice. Pharmacology 28 (1984) 296-300
9. Cain S.J., and Chau P.C. Transition probability cell cycle model. I. Balanced growth. J. Theor. Biol. 185 (1997) 55-67
10. Clairambault J. Modelling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance. Adv. Drug Deliv. Rev. 59 (2007) 1054-1068
11. El Kouni M.H., Naguib F.N.M., Park K.S., Cha S., Darnowski J.W., and Soong S.J. Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. Biochem. Pharmacol. 40 (1990) 2479-2485
12. Filipski E., Innominato P., Wu M., Li X.M., Iacobelli S., Xian L.J., and Lévi F. Effects of light and food schedules on liver and tumor molecular clocks in mice. J. Natl. Cancer Inst. 97 (2005) 507-517
13. Focan C. Rhythms of cancer chemotherapy. In: Redfern P. (Ed). Chronotherapeutics (2003), Pharmaceutical Press, London, Chicago 235-282
14. Fu L., Pelicano H., Liu J., Huang P., and Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111 (2002) 41-50
15. Gachon F., Olela F., Schaad O., Descombes P., and Schibler U. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 4 (2006) 25-36
16. Gery S., Komatsu N., Baldjyan L., Yu A., Koo D., and Koeffler H. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol. Cell 22 (2006) 375-382
17. Goldbeter A., and Claude D. Time-patterned drug administration: insights from a modeling approach. Chronobiol. Int. 19 (2002) 157-175
18. Granda T., and Lévi F. Tumor based rhythms of anticancer efficacy in experimental models. Chronobiol. Int. 19 (2002) 21-41
19. Granda T.G., D'Attino R.M., Filipski E., Vrignaud P., Garufi C., Terzoli E., Bissery M.C., and Lévi F. Circadian optimization of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Brit. J. Cancer 86 (2002) 999-1005
20. Granda T.G., Liu X.H., Smaaland R., Cermakian N., Filipski E., Sassone-Corsi P., and Lévi F. Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumour. FASEB J. 19 (2005) 304-306
21. Harris B.E., Song R., Soong S.J., and Diasio R.B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadioan variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50 (1990) 197-201
22. Haus E., Halberg F., Pauly J.E., Cardoso S., Kühl J.F., Sothern R.B., Shiotsuka R.N., and Hwang D.S. Increased tolerance of leukemic mice to arabinosyl cytosine with schedule adjusted to circadian system. Science 177 (1972) 80-82
23. Hirayama J., Cardone L., Doi M., and Sassone-Corsi P. Common pathways in circadian and cell cycle clocks: light-dependent activation of Fos/AP-1 in zebrafish controls CRY-1a and WEE-1. Proc. Natl Acad. Sci. U.S.A. 102 (2005) 10194-10199
24. Hrushesky W.J., Lévi F.A., Halberg F., and Kennedy B.J. Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats. Cancer Res. 42 (1982) 945-949
25. Lévi F. Chronopharmacology of anticancer agents. In: Redfern P.H., and Lemmer B. (Eds). Physiology and Pharmacology of Biological Rhythms (Handbook of Experimental Pharmacology) vol. 125 (1997), Springer-Verlag, Berlin 299-331
26. Lévi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2 (2001) 307-315
27. Lévi, F., 2008. Personnalized chronotherapeutics of cancer. The Endocrine Society's 90th Annual Meeting, ENDO 2008, June 15-18, 2008, San Francisco, USA, Abstract S24-3, p. 42.
28. Lévi F., Altinok A., Clairambault J., and Goldbeter A. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Philos. Trans. A: Math. Phys. Eng. Sci. 366 (2008) 3575-3598
29. Lévi F., Filipski E., Iurisci I., Li X.M., and Innominato P. Crosstalks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb Symp. Quant. Biol. 72 (2007) 465-475
30. Lévi F., Focan C., Karaboué A., de la Valette V., Focan-Henrard D., Baron B., Kreutz M., and Giacchetti S. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv. Drug Deliv. Rev. 59 (2007) 1015-1035
31. Lévi F., Metzger G., Massari C., and Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet. 38 (2000) 1-21
32. Lévi F., and Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 593-628
33. Lévi F., Zidani R., Vannetzel J.M., Perpoint B., Focan C., Faggiuolo R., Chollet P., Garufi C., Itzhaki M., and Dogliotti L. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl. Cancer Inst. 86 (1994) 1608-1617
34. Lévi F., Zidani R., and Misset J.L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350 (1997) 681-686
35. Li X.M., Metzger G., Filipski E., Lemaigre G., and Lévi F. Modulation of nonprotein sulphydryl compounds rhythm with buthionine sulphoximine: relationship with oxaliplatin toxicity in mice. Arch. Toxicol. 72 (1998) 574-579
36. Li X.M., Kanekal S., Crépin D., Guettier C., Carrière J., Elliott G., and Lévi F. Circadian pharmacology of l-alanosine (SDX-102) in mice. Mol. Cancer Ther. 5 (2006) 337-346
37. Matsuo T., Yamaguchi S., Mitsui S., Emi A., Shimoda F., and Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 302 (2003) 255-259
38. Metzger G., Massari C., and Etienne M.C. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in cancer patients. Clin. Pharm. Ther. 56 (1994) 190-201
39. Naguib F.N., Soong S.J., and El Kouni M.H. Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines. Biochem. Pharmacol. 45 (1993) 667-673
40. Nowakowska-Dulawa E. Circadian rhythm in 5-fluorouracil (FU) pharmacokinetics and tolerance. Chronobiologia 17 (1990) 27-35
41. Ohdo S., Koyanagi S., Suyama H., Higuchi S., and Aramaki H. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nature Med. 7 (2001) 356-360
42. Peters G.J., Van Dijk J., Nadal J.C., Van Groeningen C.J., Lankelma J., and Pinedo H.M. Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In Vivo 1 (1987) 113-117
43. Petit E., Milano G., Lévi F., Thyss A., Bailleul F., and Schneider M. Circadian varying plasma concentration of 5-FU during 5-day continuous venous infusion at constant rate in cancer patients. Cancer Res. 48 (1988) 1676-1679
44. Popovic P., Popovic V., and Baughman J. Circadian rhythm and 5-fluorouracil toxicity in C3H mice. Prog. Clin. Biol. Res. 107 (1982) 185-187
45. Porsin B., Formento J.L., Filipski E., Etienne M.C., Francoual M., Renée N., Lévi F., and Milano G. Dihydropyrimidine dehydrogenase circadian rhythm in both enzyme activity and gene expression from mouse liver. Eur. J. Cancer 39 (2003) 822-828
46. Reddy A.B., Wong G.K.Y., O'Neill J., Maywood E.S., and Hastings M.H. Circadian clocks: neural and peripheral pacemakers that impact upon the cell division cycle. Mutat. Res. 574 (2005) 76-91
47. Smaaland R., Sothern R.B., Laerum O.D., and Abrahamsen J.F. Rhythms in human bone marrow and blood cells. Chronobiol. Int. 19 (2002) 101-127
48. Smith J.A., and Martin L. Do cells cycle?. Proc. Natl. Acad. Sci. U.S.A. 70 (1973) 1263-1267
49. Tampellini M., Filipski E., Liu X.H., Lemaigre G., Li X.M., Vrignaud P., François E., Bissery M.C., and Lévi F. Docetaxel chronopharmacology in mice. Cancer Res. 58 (1998) 3896-3904
50. Voland C., Bord A., Péleraux A., Pénarier G., Carrière D., Galiègue S., Cvitkovic E., Jbilo O., and Casellas P. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol. Cancer Ther. 5 (2006) 2149-2157
51. Wood P.A., Du-Quiton J., You S., and Hrushesky W.J. Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol. Cancer Ther. 8 (2006) 2023-2033
52. Wu M.W., Xian L.J., Li X.M., Innominato P., and Lévi F. Circadian expression of dihydropyrimidine dehydrogenase, thymidylate synthase, c-myc and p53 mRNA in mouse liver tissue. Ai Zheng 23 (2004) 235-242
53. Zeng Z.L., Sun J., Guo L., Li S., Wu M.W., Qiu F., Jiang W.Q., Lévi F., and Xian L.J. Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients. Chronobiol. Int. 22 (2005) 741-754
54. Zhang R., Lu Z., Liu T., Soong S.J., and Diasio R.B. Relationship between circadian dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res. 53 (1993) 2816-2822